October 4, 2024
San Carlos Biotech Startup Integrated Biosciences Raises $17.2M Seed Funding to Target Age-Related Diseases
San Carlos, California, United States - October 3, 2024 -
Integrated Biosciences, a biotech company focused on combining synthetic biology and machine learning to develop therapeutics for age-related diseases, has successfully raised $17.2M in a seed funding round. The funding, led by Sutter Hill Ventures, includes participation from Root Ventures, Illumina Ventures, Civilization Ventures, Lifespan Vision Ventures, Conscience VC, Overlap Holdings, SH fund, Mission Biocapital, Reinforced Ventures, Polymath Capital, Michael Stoppelman, Sabrina Hahn, Vijay Pandurangan. This financing will be used to advance the development of its drug discovery platform and accelerate commercialization efforts for its next-generation therapeutics.
About the company
Founded in September 2022, Integrated Biosciences is focused on addressing age-related cellular stress responses. The company aims to discover small-molecule drugs that target pathways relevant to aging and age-related diseases using their proprietary AI platform and synthetic biology techniques. The company has a clear vision to revolutionize how drugs are developed for conditions like Alzheimer's, cardiovascular disease, and other aging-associated diseases by focusing on fundamental cellular mechanisms. Their innovative use of synthetic biology and machine learning allows them to generate large amounts of highly specific data, helping them identify novel therapeutic targets.
Purpose of financing
The funds will also help the company advance its preclinical-stage drug candidates. Integrated Biosciences is using its platform to identify novel drug targets and modulate biological pathways in a highly specific way. Integrated Biosciences plans to use the funds to accelerate their drug development pipeline and explore new therapeutic applications for age-related diseases. The new capital will be invested in scaling up their drug discovery efforts, with plans to bring more therapies to market faster.
What the company’s official has to add
"Our goal is to make real progress in targeting aging," "This funding allows us to expand our synthetic biology and AI platform and move towards clinical development. We are excited to be supported by visionary investors who share our commitment to improving human health."
—- said Felix Wong, Ph.D., CEO and Co-Founder of Integrated Biosciences
"Drug discovery is broken, and we are here to fix it. Our platform gives us access to the purest stress responses, which allows us to rapidly produce small molecule leads that modulate these responses in novel ways."
—- commented Max Wilson, Ph.D., Co-Founder of Integrated Biosciences
Conclusion
The company has already attracted top-tier scientific advisors, including James J. Collins, Ph.D., from MIT, and Sir David W. C. MacMillan, Ph.D., Nobel Laureate in Chemistry. With such strong backing from both investors and scientific experts, Integrated Biosciences is poised to make significant strides in the field of aging therapeutics.
With this new round of funding, Integrated Biosciences is set to continue its mission of improving human health by targeting age-related diseases at their core. The company’s unique combination of advanced technologies promises to speed up drug development and bring more effective therapies to the market in the near future.
LinkedIn